



Abbott

**ENABLE TIMELY
TREATMENT**

**WITH DIFFERENTIAL DIAGNOSIS OF
COVID-19 AND FLU A&B IN THE SAME
VISIT USING A SINGLE SWAB**



How will you achieve differential diagnosis¹ and prescribe timely treatment for COVID-19 and Flu?

CHALLENGES

- Co-circulating respiratory viruses²⁻³ and overlapping symptoms⁴⁻⁵
- Short time⁶⁻⁷ window for optimum treatment
- Unpredictability of SARS-CoV-2 and Influenza viruses

Panbio™ COVID-19/Flu A&B Rapid Panel (Nasopharyngeal)



- ✓ Distinguish between COVID-19 and Flu A&B
- ✓ Make differential diagnosis faster
- ✓ Make clinical decisions during a patient's office visit
- ✓ Test faster. Treat faster. Trace faster.

Obtain a differential diagnosis to accelerate a care pathway

Panbio™ COVID-19/Flu A&B Rapid Panel Nasopharyngeal (NP) can help support the transition from presumptive to differential diagnosis.



Panbio™ COVID-19/Flu A&B Rapid Panel (NP) utilizes one nasopharyngeal swab to perform an antigen test for 3 pathogens: SARS-CoV-2, Influenza A, and Influenza B.



RELIABLE PERFORMANCE

TEST AND TREAT WITH CONFIDENCE⁹

	COVID-19	COVID-19 (Ct≤30)	FLU A	FLU B
SENSITIVITY	88.0%	94.4%	92.0%	100%
SPECIFICITY	100%	100%	100%	100%
95% CI (ens.)	80% - 93.6%	87.5% - 98.2%	80.8% - 97.8%	92.9% - 100%
95% CI (Spec.)	98.2% - 100%	98.2% - 100%	98.2% - 100%	98.2% - 100%

Panbio™ is the trusted brand used in more than 100 countries.



CONVENIENCE

PERFORM THE TEST IN YOUR OFFICE¹⁰

Test kit with minimal steps and convenient features such as **pre-filled buffer tubes** make testing easy.⁹



RESULTS IN 15 MINUTES

MAKE RAPID, INFORMED CLINICAL DECISIONS¹¹

Perform a 3-in-1 antigen test on patients **during their visit to your office** with reliable results in **15 minutes**.⁹



DECENTRALIZATION CAN PROVIDE GREATER ACCESS TO TESTING

SCALABILITY.

Panbio™ COVID-19/Flu A&B Rapid Panel (Nasopharyngeal) offers versatility for healthcare professionals to mobilize and deploy testing at scale and speed.

POWERFUL

WORKFLOW FIT. SPEED. CONVENIENCE.

Panbio™ COVID-19/Flu A&B Rapid Panel (Nasopharyngeal) is a **powerful** diagnostic tool to identify respiratory disease, **enabling rapid treatment decisions**, and helping to reduce the spread of infection via early identification and isolation of infected individuals.^{8,10}

CONNECTED

DIGITAL TOOLS FOR GREATER VISIBILITY & CONTROL.

Abbott can provide connectivity solutions that empower stakeholders within any health system with deep insights into test data, reports and surveillance, unlocking the power of connected health.¹¹

CONTACT YOUR LOCAL ABBOTT REPRESENTATIVE TODAY OR VISIT [ABBOTT.COM/POCT](https://www.abbott.com/poct)

REFERENCES

1. CDC Similarities and Differences between Flu and COVID-19, Jan 2022. <https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm>
2. CDC. Testing Guidance for Clinicians When SARS-CoV-2 and Influenza Viruses are Co-circulating. <https://www.cdc.gov/flu/professionals/diagnosis/testing-guidance-for-clinicians.htm>
3. Cavin S, Rutherford GW. Coinfection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and Influenza: An Evolving Puzzle. *Clin Infect Dis*. 2021;72(12):e993-e994. doi:10.1093/cid/ciaa1810 <https://pubmed.ncbi.nlm.nih.gov/33277660/>
4. COVID-19 and Flu: Identifying the Symptoms; <https://www.health.gov.au/sites/default/files/documents/2020/05/coronavirus-covid-19-identifying-the-symptoms.pdf>
5. Symptoms of COVID-19, <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html#self-checker>
6. Early Administration of Oseltamivir Within 48 Hours After Onset of Flu-like Symptoms Can Reduce the Risk of Influenza B Virus-Associated Pneumonia in Hospitalized Pediatric Patients with Influenza B Virus Infection. *Pediatr Infect Dis J*. 2020 Feb;39(2):e20-e22. doi: 10.1097/INF.0000000000002528. PMID: 31929434 <https://pubmed.ncbi.nlm.nih.gov/10921934/>
7. Talha Khan Burki, The role of antiviral treatment in the COVID-19 pandemic, *The Lancet Respiratory Medicine*, [https://doi.org/10.1016/S2213-2600\(22\)00011-X](https://doi.org/10.1016/S2213-2600(22)00011-X)
8. Interim Guidance for Antigen Testing for SARS-CoV-2; <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html#using-antigen-tests-community-settings>
9. Panbio™ COVID-19/Flu A&B Rapid Panel (Nasopharyngeal) IFU
10. CDC, Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing <https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html>
11. Barenfanger J, Drake C, Leon N, Mueller T, Trout T. Clinical and financial benefits of rapid detection of respiratory viruses: an outcomes study. *J Clin Microbiol*. 2000;38(8):2824-2828. doi:10.1128/JCM.38.8.2824-2828.2000 <https://journals.asm.org/doi/10.1128/JCM.38.8.2824-2828.2000>

Product not available in all countries.

© 2022 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model.

COL-07666-01 05/22

